(Q35579711)

9 August 2017

title

Modafinil in the treatment of excessive daytime sleepiness in children (English)

1 reference

excessive daytime sleepiness

9 August 2017

1 reference

1 reference

3

David Gozal

1 reference

9 August 2017

Anna Ivanenko

1

1 reference

9 August 2017

Riva Tauman

series ordinal

2

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

number of pages

4

1 reference

inferred from page(s)

published in

Sleep Medicine

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

579-582

1 reference

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Hypothalamic arousal regions are activated during modafinil-induced wakefulness.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Modafinil for narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Modafinil augmentation of antidepressant treatment in depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Is psychosis exacerbated by modafinil?

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

Dopaminergic role in stimulant-induced wakefulness.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-9457%2803%2900162-X

7 January 2021

10.1016/S1389-9457(03)00162-X

Identifiers

DOI

1 reference

9 August 2017

1 reference